Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from human plasmacytoid dendritic cells treated with p17 or CpG

ABSTRACT: We used microarrays to detail the global program of gene expression underlying the effect of p17 on human plasmacytoid dendritic cells and was compared to CpG profile. Keywords: gene expression study

ORGANISM(S): Homo sapiens

PROVIDER: GSE10147 | GEO | 2008/02/14

SECONDARY ACCESSION(S): PRJNA108697

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of human plasmacytoid dendritic cells treated with p17 or CpG

Project description:We used microarrays to detail the global program of gene expression underlying the effect of p17 on human plasmacytoid dendritic cells and was compared to CpG profile. Experiment Overall Design: Human plasmacytoid dendritic cells were purified from two donors and cultured in the presence of p17 or CpG for 18 h.

2008-04-07 | E-GEOD-10147 | biostudies-arrayexpress

Effect of IVIG on the activation of plasmacytoid dendritic cells

Project description:To investigate the effect of IVIG and desialylated IVIG on the activation of plasmacytoid dendritic cells (pDCs). Human primary plasmacytoid dendritic cells were treated with TLR stimulation together with or without IVIG or desialylated IVIG, and the change of genes were analyzed. Primary human pDCs were preincubated with or without 10mg/ml IVIG or desialylated IVIG followed by stimulation with CpG overnight. The different genes between IVIG+CpG and desialylated IVIG+CpG were analyzed.

2022-07-04 | GSE207028 | GEO

Methylation data profiling for blastic plasmacytoid dendritic cell neoplasm

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy assumed to originate from plasmacytoid dendritic cells (pDCs), which affects the skin and bone marrow and sequentially other organ systems. Here, we used EPIC arrays to characterize methylation profiles in 51 BPDCN cases.

2024-02-11 | GSE230487 | GEO

Transcription profiling of human monocyte-derived dendritic cells after treatment with with CpG-oligo D19

Project description:Human monocyte-derived dendritic cell cultures devoid of contaminating plasmacytoid dendritic cells were treated with the D-type CpG-oligonucleotide D19, with the non-CpG-oligonucleotide control D, or were left untreated. Cells of all treatment groups stemmed from the same donor. 6 h after addition, cells were harvested, and total RNA was prepared for analysis of D19-dependent differential gene expression on Affymetrix HG-U 133A 2.0. Experiment Overall Design: One sample per treatment-group. No replicates.

2008-06-12 | E-GEOD-2859 | biostudies-arrayexpress

Differential gene expression after treatment of human monocyte-derived dendritic cells with CpG-oligo D19

2006-06-30 | GSE2859 | GEO

Expression data from mouse plasmacytoid dendritic cells stimulated with CpG and treated with lif

Project description:Expression data from mouse plasmacytoid dendritic cells stimulated with CpG and treated with lif

| PRJNA574156 | ENA

GFI deficiency in plasmacytoid dendritic cells

Project description:Growth factor independence genes (Gfi1 and Gfi1b) repress recombination activating genes (Rag) transcription in developing B lymphocytes. Because all blood lineages originate from hematopoietic stem cells (HSCs) and different lineage progenitors have been shown to share transcription factor networks prior to cell fate commitment, we hypothesized that GFI family proteins may also play a role in repressing Rag transcription or a global lymphoid transcriptional program in other blood lineages. We tested the level of Rag transcription in various blood cells when Gfi1 and Gfi1b were deleted, and observed an upregulation of Rag expression in plasmacytoid dendritic cells (pDCs). Using microarray analysis, we observed that Gfi1 and Gfi1b regulate a broad spectrum of cellular processes in pDCs, but not a lymphoid specific transcriptional program. This study establishes a role for Gfi1 and Gfi1b in Rag regulation in a non-B lineage cell type Gfi1f/f; Gfi1bf/f; ERCre bone marrow progenitors were untreated and treated with tamoxifen (4OHT) to delete floxed alleles during pDC differentiation in culture. Cells from three individual mouse constitute triplicates of untreated (-4OHT) and treated (+4OHT) conditions, corresponding to wildtype or knockout genotypes.

2013-04-07 | E-GEOD-45837 | biostudies-arrayexpress

Blastic plasmacytoid dendritic cell neoplasm (BPDCN)_cases

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that is most similar in expression profiles to plasmacytoid dendritic cells. However, patients often exhibit features of AML and can progress to AML. In this project, we will determine the differentially and commonly expressed genes between BPDCN and AML specimens. Available BPDCN and TET2-mutated AML specimens were taken for transcriptome microarray analysis.

| EGAD00010001727 | EGA

Molecular landscape of blastic plasmacytoid dendritic cell neoplasm

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignancy assumed to originate from plasmacytoid dendritic cells (pDCs), which mostly affects the skin, bone marrow and lymph nodes and sequentially other organ systems. We applied paired WES/RNA-seq combined with genome-wide copy-number analysis to characterize 47 BPDCN patients regarding mutational drivers, cytogenetic aberrations and gene-expression profiles.

| EGAS00001006166 | EGA

A Druggable TCF4- and BRD4-dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm (ATAC-Seq)

Project description:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and largely incurable hematologic malignancy originating from plasmacytoid dendritic cells (pDCs). Using RNA interference screening, we identified the E-box transcription factor TCF4 as a master regulator of the BPDCN oncogenic program. TCF4 served as a faithful diagnostic marker of BPDCN, and its downregulation caused the loss of the BPDCN-specific expression program and apoptosis. High-throughput drug screening revealed that bromodomain and extra-terminal domain inhibitors (BETi's) induce BPDCN apoptosis, which was attributable to disruption of the TCF4-dependent transcriptional network and loss of BPDCN-specific super-enhancers. BETi's retarded the growth of BPDCN xenografts, supporting their clinical evaluation in this recalcitrant malignancy.

2016-11-15 | GSE84623 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data